Innate Lymphoid Cells and Inflammatory Bowel Disease

Area of Science:

• Immunology
• Cell Biology
• Gastroenterology

Background:

• Adaptive immunity relies on antigen-specific receptors, but some lymphoid cells lack these.
• These cells are termed innate lymphoid cells (ILCs), including natural killer (NK) cells and lymphoid tissue-inducing cells (LTi).
• Further ILC subsets (ILC1, ILC2, ILC3) are defined by cytokine production (IFNγ, IL-5/IL-13, IL-22/IL-17, respectively).

Purpose of the Study:

• To review the roles of innate lymphoid cells (ILCs) in intestinal inflammation.
• To discuss how ILCs amplify or regulate immune responses in the gut.
• To explore therapeutic strategies targeting ILCs for inflammatory bowel disease (IBD).

Main Methods:

• This review synthesizes existing research on ILCs and their function in the gut.
• It examines the mechanisms by which ILCs influence adaptive immunity and myeloid cells.
• The review discusses the link between ILC dysregulation and IBD pathogenesis.

Main Results:

• ILCs rapidly secrete cytokines upon activation, unlike slower adaptive lymphocytes.
• ILCs can directly modulate adaptive lymphocytes and myeloid cells.
• Proper ILC function is crucial for maintaining intestinal homeostasis and pathogen defense.

Conclusions:

• Dysregulated ILC activity in the gut contributes to inflammatory bowel disease (IBD).
• ILCs are critical players in both initiating and resolving intestinal inflammation.
• Targeting ILCs presents a promising avenue for developing novel IBD therapies.